AUS
NZ
UK
CA
USA
IND
Headlines
- Wealthcare Advisory Reduces Stake in MetLife (NYSE:MET)
- Notable Changes in MetLife’s Institutional Investor Holdings
- Analyst Ratings Update on MetLife
Wealthcare Advisory Partners LLC has reduced its holdings in MetLife, Inc. by a notable percentage during the most recent quarter. This move reflects a shift in the institutional investor's position in the company, which has attracted significant attention from other large investors and analysts alike.
Wealthcare’s recent filing with the Securities and Exchange Commission reveals that it reduced its stake in MetLife by 33.6% during the fourth quarter. As of the latest filing, Wealthcare Advisory held 5,920 shares of MetLife, following the sale of 3,001 shares during the period. Despite the reduction, the remaining shares still hold considerable value, reflecting the company's strong presence in the financial services sector.
In addition to Wealthcare’s adjustments, several other institutional investors have made substantial changes to their positions in MetLife. Zurich Insurance Group Ltd FI entered a new position in MetLife during the third quarter, showcasing confidence in the financial giant. BNP Paribas Asset Management Holding S.A. also made a significant move, boosting its holdings by nearly 80%. This increase brought the company's total shares in MetLife to over 1.7 million, reflecting a commitment to the stock with a value reaching over $140 million.
Jacobs Levy Equity Management Inc. was another major player, increasing its stake in MetLife by more than 250%. The firm now holds nearly a million shares of the financial services provider. Meanwhile, Nordea Investment Management AB raised its position by 16.8%, bringing its total to over 4.2 million shares. Public Sector Pension Investment Board also made notable moves, increasing its stake by a significant margin, now owning over 430,000 shares.
Despite these institutional maneuvers, institutional investors overall hold a dominant share of MetLife, with their combined ownership surpassing 94%. This continued institutional interest underlines the stability and long-term potential many investors see in the company.
The recent shifts have not gone unnoticed by analysts, who have issued several reports on MetLife in recent months. Some have even raised their target prices, reflecting a more optimistic view of the company’s future. Piper Sandler, for instance, increased its price target for MetLife from $85 to $92, offering a favorable outlook for the stock. Similarly, Jefferies Financial Group raised its target price to $95, reinforcing confidence in the company’s performance.
Wells Fargo & Company made a more modest adjustment, reducing its price target slightly from $93 to $92 while keeping an overweight rating on the stock. Barclays also made a positive revision, raising its target price for MetLife to $96, reflecting its belief in the company's strong prospects.
The financial services sector, particularly insurance providers like MetLife, continues to see varying perspectives from institutional investors and analysts. These shifts in institutional positions and the changes in analyst ratings underscore the dynamic nature of investment strategies in this industry. As MetLife continues to adapt to changing market conditions, the next few quarters will likely provide further insights into its long-term potential.
